Beckford, R. and Shah, G. (2010) Thrombotic Thrombocytopenic Purpura: A Review of the Disease Entity, Its Clinical and Laboratory Features, and Management Strategies. The Medicine Forum, 12, 12-15.
https://doi.org/10.29046/TMF.012.1.005

has been cited by the following article:

• TITLE: What the Internist Should Know about Thrombotic Microangiopathies

  AUTHORS: Marjan Alidoost, Attiya Haroon, Varsha Gupta, Arif Asif, Mohammad A. Hossain

  KEYWORDS: TMA, aHUS, HUS, TTP

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.10 No.12, December 19, 2019

  ABSTRACT: Thrombotic microangiopathy (TMA) is a group of diseases that are life-threatening and can lead to end organ damage (EOD) due to ischemia caused by microthrombi in capillaries and arterioles. TMAs can affect any organ system but usually affect the kidney, intestines, and nervous system. The triad of TMA is Coombs-negative hemolytic anemia with schistocytes seen on peripheral smear, thrombocytopenia (platelets under 150,000 or a decrease of 25% or more from baseline), and evidence of ischemic EOD. Primary TMAs include Thrombotic Thrombocytopenic Purpura (TTP), Hemolytic Uremic Syndrome (HUS) and atypical HUS (aHUS). Pathophysiologically, all of these diseases are caused by aggregation of von Willebrand Factor (vWF) multimers, via different mechanisms, which eventually leads to thrombus formation. TTP and aHUS benefit from plasma exchange (PEX), whereas HUS is treated symptomatically. Urgent recognition with timely treatment is crucial to managing these potentially life-threatening conditions.